Receive a weekly summary and discussion of the top papers of the week by leading researchers in the field.

In Cancer treatment reviews

Colon cancer (CC) has the highest incidence rate among gastrointestinal cancers and ranks the third in mortality among all cancers, which contributes to the current CC burden and constitutes a major public health issue. While therapeutic strategies for stage I, III, and IV CC are standardized, those for stage II CC remain debatable. The choice of adjuvant chemotherapy for patients with stage II CC depends on stage (pT4) and grade (high) of the disease, the presence of venous, perinervous, and/or lymphatic emboli, or the need of suboptimal surgery (tumor with initial occlusion or perforation needing emergency surgeries, <12 lymph nodes harvested). Several prognostic factors that have been validated in retrospective studies can potentially define a population of CC patients at low and high-risk for reccurence. The role of biomarkers is becoming increasingly important for the future personalized treatment options. We conducted a systematic overview of potential prognostic biomarkers with possible clinical implications in stage II CC.

Parent Pauline, Cohen Romain, Rassy Elie, Svrcek Magali, Taieb Julien, André Thierry, Turpin Anthony


Adjuvant chemotherapy, Artificial intelligence, Carcinoembryonic antigen, Circulating Tumor DNA, Colorectal cancer, Immunoscore